Key Differences in Y90 vs. SBRT Dosing in HCC

Role of Radiotherapy in HCC (Hepatocellular Carcinoma):

Radiotherapy plays a critical role in treating HCC, particularly for patients who are not candidates for surgery or liver transplantation. It aims to deliver targeted radiation to destroy tumor cells while sparing healthy liver tissue. Advanced techniques, such as SBRT and Y90 radioembolization, are commonly used for localized disease and provide non-invasive tumor control with minimal systemic side effects.

What is Y90?

Y90 (Yttrium-90) radioembolization is a locoregional therapy that involves injecting radioactive microspheres directly into the hepatic artery, targeting liver tumors. These microspheres lodge in the tumor's arterioles and emit beta radiation, delivering a highly localized dose over several days. The radiation penetrates only 2–3 mm into tissue, resulting in a heterogeneous dose distribution within the tumor.

What is SBRT?

SBRT (Stereotactic Body Radiation Therapy) is a highly precise form of external beam radiation therapy that delivers intense doses of radiation to the tumor in a few sessions, typically over a few minutes per session. SBRT is known for delivering a uniform dose of radiation, with high tumor control rates due to its precision and ability to spare surrounding healthy tissue.

Key Differences in Y90 vs. SBRT Dosing in HCC:

1. Dose Uniformity: SBRT delivers a uniform dose across the tumor, while Y90 provides a highly heterogeneous dose due to microsphere deposition in arterioles with limited penetration (2–3 mm).

2. Dose Distribution: Y90 doses vary significantly within the tumor mass, whereas SBRT provides consistent dosing throughout the target region.

3. Dose Rate: SBRT administers radiation over minutes per session, while Y90 delivers radiation gradually over several days due to Y90's half-life (~64 hours).

4. Biological Effect: Y90's slower radiation delivery allows cellular repair of sublethal DNA damage during treatment, reducing its biological effectiveness per Gy compared to SBRT.

5. Dose Equivalence: A Y90 dose of ~400 Gy corresponds to an SBRT dose of 40–50 Gy in terms of tumoricidal effect due to the temporal protraction effect.

Summary of the Text:

Radiotherapy is crucial for treating HCC, especially for patients ineligible for surgery. Y90 is a locoregional therapy using radioactive microspheres to deliver heterogeneous radiation over days, while SBRT is a precise external beam therapy delivering uniform radiation in minutes. Key differences include dose uniformity, distribution, rate, biological effects, and equivalence, with Y90's 400 Gy being biologically similar to SBRT's 40–50 Gy.